Pharmaceutical Litigation Attorneys
In 2012, Novartis, a large pharmaceutical company, made the decision to voluntarily recall one if its drugs, Valturna. Made with two medications, aliskiren and valsartan, Valturna is a type of prescription medication used to treat high blood pressure. Originally approved by the U.S. Food & Drug Administration is 2009, Valturna has been linked with an increased risk of certain dangerous—and even deadly—health consequences.
Studies Point to Increased Risk of Health Complication When Taking Valturna
When Valturna was tested for its safety and effectiveness by an independent commission (after Valturna had already been put on the market), the study shed light on evidence that taking Valturna significantly increased a patient’s risk of:
- Stroke;
- Renal complications;
- Hyperkalemia; and
- Low blood pressure.
According to the study and an
April 2012 safety communication published by the FDA, the primary cause of the complications listed above is the ingredient aliskiren. Taking aliskiren can increase a patient’s risk of death.
Take Action Today
Because of the statute of limitations, which limits the amount of time that you have to file a claim after being harmed by a defective drug, it is imperative that you consult with a
pharmaceutical litigation attorney near you now. At Napoli Shkolnik, PLLC, our attorneys have offices in multiple states, and can help you no matter where you are located.
January 21, 2026
For PFAS in biosolids, 2025 was the year statehouses stepped decisively into the vacuum. While federal policy is evolving, state and local governments are rapidly redrawing the rules...
Read the Article
January 14, 2026
Bringing a baby into the world is supposed to be joyful. When something goes wrong during pregnancy, labor, or delivery, that joy can be replaced in an instant...
Read the Article
January 7, 2026
The holiday season is meant for connection and celebration, but travel can add unexpected pressure. Beginning at the end of November, more drivers take to the roads, increasing...
Read the Article